| Literature DB >> 22363249 |
Yang-Chang Wu1,2, Jui-Hsin Su3,4, Tai-Ting Chou5, Yin-Pin Cheng5, Ching-Feng Weng3,6, Chia-Hung Lee3,6, Lee-Shing Fang7, Wei-Hsien Wang4,8,9, Jan-Jung Li4, Mei-Chin Lu3,4, Jimmy Kuo3,4, Jyh-Horng Sheu8,9, Ping-Jyun Sung3,4,6,8,9.
Abstract
The structures, names, bioactivities, and references of 81 new secondary metabolites obtained from gorgonian corals belonging to the genus Junceella are described in this review. All compounds mentioned in this review were obtained from sea whip gorgonian corals Junceella fragilis and Junceella juncea, collected from the tropical and subtropical Indo-Pacific Ocean.Entities:
Keywords: Indo-Pacific Ocean; Junceella; South China Sea; briarane; gorgonian
Mesh:
Substances:
Year: 2011 PMID: 22363249 PMCID: PMC3280581 DOI: 10.3390/md9122773
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
The new natural products from Junceella fragilis-I.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| (−)-2-Deacetyljunceellin (R1 = OH, R2 = OAc) | n.r. | [ | ||
| (−)-3-Deacetyljunceellin (R1 = OAc, R2 = OH) | n.r. | [ |
n.r. = not reported.
The new natural products from Junceella fragilis-II.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| Junceellonoid A | n.r. | [ | ||
| Junceellonoid B | n.r. | [ | ||
| Junceellonoid C | exhibited cytotoxicity toward MDA-MB-231 and MCF-7 cells at a concentration of 100 µM | [ | ||
| Junceellonoid D (R1 = R2 = OH) | exhibited cytotoxicity toward MDA-MB-231 and MCF-7 cells at a concentration of 100 µM | [ | ||
| Junceellonoid E (R1 = R2 = OAc) | n.r. | [ |
n.r. = not reported.
The new natural products from Junceella fragilis-III.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| 9- | n.r. | [ | ||
| Junceellolide H | not active in cytotoxicity testing with P-388D1, DLD-1, IMR-32, RPMI 7951 and CCRF-CEM tumor cells | [ | ||
| Junceellolide I | n.r. | [ | ||
| Junceellolide J | not active in anti-inflammatory bioassay | [ | ||
| Junceellolide K | weakly anti-inflammatory | [ | ||
| Junceellolide L | not active in anti-inflammatory bioassay | [ | ||
| Fragilide A | n.r. | [ | ||
| Fragilide B (R1 = OC(O)CH2CH3, R2 = H) | weakly anti-inflammatory | [ | ||
| Fragilide G (R1 = R2 = OAc) | not active in cytotoxicity testing with DLD-1 and CCRF-CEM cells | [ | ||
| Fragilide C (R1 = OCOCH2CH3, R2 = H, R3 = OH) | weakly anti-inflammatory | [ | ||
| Fragilide J (R1 = OH, R2 = OAc, R3 = H) | weakly anti-inflammatory | [ | ||
| Fragilide D (= Frajunolide G) (R = OC(O)CH2OC(O)CH2CH(CH3)2) | n.r. | [ | ||
| Fragilide E (R1 = β-OH, R2 = α-CH2OAc) | weakly anti-inflammatory | [ | ||
| Fragilide F (R1 = α-OH, R2 = β-CH2Cl) | not active in cytotoxicity testing with DLD-1 and CCRF-CEM cells | [ | ||
| I | Fragilide H | not active in cytotoxicity testing with P-388D1, DLD-1, HL-60 and CCRF-CEM cells | [ | |
| Fragilide I (R = OC(O)CH2CH(CH3)2) | not active in cytotoxicity testing with P-388D1, DLD-1, HL-60 and CCRF-CEM cells | [ | ||
| Frajunolide A (R1 = α-OAc, R2 = H) | weakly anti-inflammatory | [ | ||
| Frajunolide B (R1 = α-OAc, R2 = OAc) | weakly anti-inflammatory | [ | ||
| Frajunolide E (R1 = H, R2 = OAc) | frajunolides E, J and L were weakly anti-inflammatory | [ | ||
| Frajunolide J (R1 = α-OC(O)Et, R2 = H) | frajunolides E and J were not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | [ | ||
| Frajunolide L (R1 = β-OAc, R2 = H) | [ | |||
| Frajunolide C (R = Cl) | weakly anti-inflammatory | [ | ||
| Frajunolide D (R = OAc) | not active in anti-inflammatory bioassay | [ | ||
| Frajunolide F | weakly anti-inflammatory | [ | ||
| not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | ||||
| Frajunolide G (= Fragilide D) (R = OC(O)CH2OC(O)CH2CH(CH3)2) | not active in anti-inflammatory bioassay | [ | ||
| not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | ||||
| Frajunolide H | not active in anti-inflammatory bioassay | [ | ||
| not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | ||||
| Frajunolide I | weakly anti-inflammatory | [ | ||
| not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | ||||
| Frajunolide K (R = OC(O)CH2OC(O)CH2CH(CH3)2) | not active in anti-inflammatory bioassay | [ | ||
| Frajunolide M | weakly anti-inflammatory | [ | ||
| Frajunolide N | modestly anti-inflammatory | [ | ||
| not active in cytotoxicity testing with Hep2, Doay, WiDr and Hela cells | ||||
| Frajunolide O | weakly anti-inflammatory | [ |
n.r. = not reported; P388D1 (mouse lymphoid neoplasm), DLD-1 (human colon adenocarcinoma), IMR-32 (human neuroblastoma), RPMI 7951 (human malignant melanoma), CCRF-CEM (human T-cell acute lymphoblastic leukemia), HL-60 (human promyelocytic leukemia), Hep2 (human liver carcinoma), Doay (medulloblastoma), WiDr (human colon adenocarcinoma), Hela (human cervical epitheloid carcinoma).
The new natural products from Junceella juncea-IV.
| Structure | No. | Name | Ref. |
|---|---|---|---|
| 4′- | [ | ||
| Junceelloside A (R1 = R2 = OH, R3 = OAc) | [ | ||
| Junceelloside B (R1 = R3 = OH, R2 = OAc) | [ | ||
| Junceelloside C (R1 = OAc, R2 = R3 = OH) | [ | ||
| Junceelloside D (R1 = R2 = R3 = OH) | [ | ||
| 1,2- | [ |
The new natural products from Junceella juncea-V.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| Juncin O (R = OC(O)CH2CH(CH3)2) | juncins O–Q showed medium antifeedant activity (90.7, 69.0, 46.5%) toward the second-instar larvae of | [ | ||
| juncins O–Q and ZII were not active in cytotoxicity testing with K562, A549, Hela and Hep2 cells | ||||
| medium cytotoxicity (cell mortality: 8.7% in 24 h and 11.9% in 48 h) toward the second-instar larvae of | ||||
| Juncin P | medium cytotoxicity (cell mortality: 25.3% in 24 h and 29.7% in 48 h) toward the second-instar larvae of | [ | ||
| Juncin Q | medium cytotoxicity (cell mortality: 31.3% in 24 h and 44.0% in 48 h) toward the second-instar larvae of | [ | ||
| Juncin X | [ | |||
| Juncin Y (R = CH2OAc) | [ | |||
| Juncin Z (R = CO(O)CH3) | [ | |||
| Juncin R (R1 = R2 = R3 = OAc, R4 = OC(O)CH2CH(CH3)2, R5 = Cl) | juncins R–ZII ( | [ | ||
| Juncin S (R1 = R3 = R4 = OAc, R2 = OC(O)CH2CH(CH3)2, R5 = Cl) | [ | |||
| Juncin T (R1 = OC(O)CH2OC(O)(CH2)2CH(CH3)2, R2 = R3 = R4 = OAc, R5 = OH) | [ | |||
| Juncin U (R1 = R2 = R4 = OAc, R3 = OC(O)CH2CH(CH3)2, R5 = OCH3) | [ | |||
| Juncin V (R1 = R3 = OAc, R2 = R4 = OH, R5 = OCH3) | [ | |||
| Juncin W (R1 = R3 = R5 = OAc, R2 = R4 = OH) | [ | |||
| Juncin ZI | [ | |||
| Juncin ZII (R = OC(O)(CH2)2CH(CH3)2) | medium antifeedant activity (84.5%) toward the second-instar larvae of | [ | ||
| medium cytotoxicity (cell mortality: 20.5% in 24 h and 43.2% in 48 h) toward the second-instar larvae of |
K562 (human erythromyeloblastoid leukemia), A549 (human lung adenocarcinoma), Hela (human cervical epitheloid carcinoma), Hep2 (human liver carcinoma).
The new natural products from Junceella juncea-VI.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| Juncin I (R1 = R3 = OAc, R2 = OCOCH2CH(CH3)2) | n.r. | [ | ||
| Juncin J (R1 = R2 = OCOCH2CH(CH3)2, R3 = OAc) | n.r. | [ | ||
| Juncin K (R1 = R3 = OCOCH2CH(CH3)2, R2 = H) | n.r. | [ | ||
| Juncin L (R1 = R2 = OCOCH2CH(CH3)2, R3 = OAc) | n.r. | [ | ||
| Juncin M (R1 = R3 = OCOCH2CH(CH3)2, R2 = H) | n.r. | [ | ||
| Juncenolide B (R = OCOCH2CH(CH3)2) | n.r. | [ | ||
| (2 | n.r. | [ |
The new natural products from Junceella juncea-VII.
| Structure | No. | Name | Biological Activity | Ref. |
|---|---|---|---|---|
| Juncenolide E | n.r. a | [ | ||
| Juncenolide F (R1 = OC(O)CH(CH3)2, R2 = OC(O)CH2CH(CH3)2) | n.r. | [ | ||
| Juncenolide H (R1 = R2 = OAc) | modestly anti-inflammatory | [ | ||
| Juncenolide I (R1 = OC(O)CH(CH3)2, R2 = OAc) | weakly anti-inflammatory | [ | ||
| Juncenolide J (R1 = OAc, R2 = OC(O)CH2CH(CH3)2) | not active in anti-inflammatory bioassay | [ | ||
| Juncenolide G | n.r. | [ | ||
| Juncenolide K | weakly anti-inflammatory | [ | ||
| Juncin N | not active in cytotoxicity testing with P-388D1, DLD-1, IMR-32, RPMI 7951 and CCRF-CEM cells b | [ | ||
| Junceol A (R = OC(O)CH2CH(CH3)2) | significantly | [ | ||
| anti-inflammatory | ||||
| Junceol B (R1 = OAc, R2 = OC(O)CH2CH(CH3)2) | significantly | [ | ||
| anti-inflammatory | ||||
| Junceol C (R1 = R2 = OC(O)CH2CH(CH3)2) | significantly | [ | ||
| anti-inflammatory | ||||
| Junceol D (R1 = OC(O)CH(CH3)2, R2 = OC(O)CH2CH(CH3)2, R3 = OAc) | not active in anti-inflammaory bioassay | [ | ||
| exhibited cytotoxicity toward CCRF-CEM and DLD-1 (IC50 = 1.3, 10.0 µg/mL) cells | ||||
| Junceol E (R1 = OC(O)CH(CH3)2, R2 = OAc, R3 = H) | weakly anti-inflammatory | [ | ||
| not active in cytotoxicity testing with CCRF-CEM and DLD-1 (IC50 > 40 µg/mL) cells | ||||
| Junceol F (R1 = OC(O)CH(CH3)CH2CH3, R2 = OAc, R3 = H) | moderately anti-inflammatory | [ | ||
| exhibited cytotoxicity toward CCRF-CEM (IC50 = 4.9 µg/mL) cells | ||||
| Junceol G (R1 = OC(O)CH(CH3)CH2CH3, R2 = H, R3 = OAc) | weakly anti-inflammatory | [ | ||
| exhibited cytotoxicity toward CCRF-CEM (IC50 = 4.4 µg/mL) | ||||
| Junceol H (R1 = OAc, R2 = H, R3 =OC(O)CH(CH3)2) | weakly anti-inflammatory | [ | ||
| exhibited cytotoxicity toward CCRF-CEM and DLD-1 (IC50 = 7.2, 17.0 µg/mL) cells |
n.r. = not reported. P388D1 (mouse lymphoid neoplasm), DLD-1 (human colon adenocarcinoma), IMR-32 (human neuroblastoma), RPMI 7951 (human malignant melanoma), CCRF-CEM (human T-cell acute lymphoblastic leukemia).
Figure 1The cultured-type gorgonian corals Junceella fragilis (white) and Junceella juncea (red).